We have located links that may give you full text access.
Case Reports
Journal Article
Bullous Sweet's syndrome and pseudolymphoma precipitated by IL-2 therapy.
IL-2 is a key cytokine in cell-mediated immunity and currently is used in clinical trials as immunologic therapy in human immunodeficiency virus (HIV)-positive patients. Although cutaneous reactions to IL-2 therapy are common, bullous reactions are rare. We report a case of an HIV-positive patient who received multiple cycles of IL-2 therapy and developed a bullous eruption soon after each cycle was initiated. Pathology results from 2 separate outbreaks revealed a diffuse dermal neutrophilic infiltrate with leukocytoclasis. Epidermal spongiosis and focal intraepidermal vesiculation also were present. The patient discontinued IL-2 therapy but restarted 5 years later, at which time he presented with a pseudolymphomatous reaction that resolved after discontinuation of therapy. This patient is an unusual case of 2 different eruptions--Sweet's syndrome and pseudolymphoma-precipitated by IL-2 therapy in the same patient. Cutaneous eruptions to IL-2 therapy also are reviewed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app